Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report by Sunanjay Bajaj, MD, Andrew Chow, MD, PhD, Alexander Drilon, MD, Or Kalchiem-Dekel, MD

Get full text

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) by Rachel E. Reingold, MD, Rose Parisi, MD, MBA, Guilherme Harada, MD, Andrea P. Moy, MD, George Dranitsaris, PhD, Jasmine H. Francis, MD, Julia Canestraro, OD, FAAO, Julia A. Lester, MPH, Lauren A. Kaplanis, RN, Dazhi Liu, PharmD, BCOP, Mario E. Lacouture, MD, Alexander Drilon, MD

Get full text

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC by Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD

Get full text